Fredriksen J H, Rosenqvist E, Wedege E, Bryn K, Bjune G, Frøholm L O, Lindbak A K, Møgster B, Namork E, Rye U
Department of Vaccine, National Institute of Public Health, Oslo.
NIPH Ann. 1991 Dec;14(2):67-79; discussion 79-80.
A vaccine against serogroup B meningococcal disease has been prepared from a B:15:P1.7,16 meningococcal strain (44/76) by fermentor growth and extraction of the bacteria with the detergent deoxycholate. Outer membrane vesicles (OMV) were purified by ultracentrifugation and adsorbed to aluminium hydroxide adjuvant. OMV contained the major class 1, 3, 4 and 5 proteins and some minor high molecular weight protein components. Relative to protein, the vaccine also contained about 8% phospholipid, 7% lipopolysaccharide and 16% deoxycholate. The product was generally non-pyrogenic to humans in ordinary doses and was highly immunogenic in mice and humans. Production and control steps, physical, chemical and immunological data for the vaccine are described.
一种针对B群脑膜炎球菌病的疫苗,是从一株B:15:P1.7,16脑膜炎球菌菌株(44/76)通过发酵罐培养并用去污剂脱氧胆酸盐提取细菌而制备的。外膜囊泡(OMV)通过超速离心纯化,并吸附到氢氧化铝佐剂上。OMV含有主要的1、3、4和5类蛋白质以及一些次要的高分子量蛋白质成分。相对于蛋白质,该疫苗还含有约8%的磷脂、7%的脂多糖和16%的脱氧胆酸盐。该产品在常规剂量下对人类一般无致热原性,在小鼠和人类中具有高度免疫原性。描述了该疫苗的生产和控制步骤、物理、化学和免疫学数据。